Form 8-K Zynerba Pharmaceuticals, For: Feb 26
Zynerba Pharmaceuticals, Inc. (ZYNE)
Last zynerba pharmaceuticals, inc. earnings: 3/10 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.zynerba.com
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
ZYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYNE alerts
High impacting Zynerba Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ZYNE
News
- Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual MeetingGlobeNewswire
- Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual MeetingGlobeNewswire
- Zynerba Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ZYNE/price-target/">NASDAQ: ZYNE</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
- Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual MeetingGlobeNewswire
- Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual MeetingGlobeNewswire
ZYNE
Earnings
- 11/15/21 - Miss
ZYNE
Sec Filings
- 4/25/22 - Form DEFA14A
- 4/25/22 - Form DEF
- 3/1/22 - Form S-8
- ZYNE's page on the SEC website